A brief description of the guidelines for use of Avapritinib

Avapritinib, as a highly efficient tyrosine kinase inhibitor, has shown significant efficacy in the treatment of gastrointestinal stromal tumors (GIST) and systemic mastocytosis (including advanced systemic mastocytosis AdvSM and indolent systemic mastocytosis ISM) in recent years. To ensure that patients can use this drug safely and effectively, a brief guide to the use of avatinib is provided below.

The recommended dose of avatinib varies based on the type of disease and the patient's liver function status. For GIST patients with PDGFRA exon 18 mutations, the recommended dose is 300 mg orally once daily until disease progression or unacceptable toxicity occurs. For AdvSM patients, it is recommended that the dose be adjusted to 200 mg orally once daily, and treatment must also be continued until disease progression or unacceptable toxicity. For patients with ISM, the recommended dose is a more cautious 25 mg, taken orally once daily.

It is worth noting that for patients with severe hepatic impairment (Child-Pugh Class C), the dose of avatinib needs to be reduced accordingly. Specifically, the dose for GIST patients is adjusted to 200 mg orally once daily; for AdvSM patients, the dose is adjusted to 100 mg orally once daily; for ISM patients, the dose is adjusted to 25 mg orally every other day.

When taking avatinib, patients should ensure that it is taken on an empty stomach at least 1 hour before meals or 2 hours after meals to ensure stable absorption of the drug and reduce adverse reactions. If the patient misses a dose and it is less than 8 hours before the next scheduled dose, there is no need to take a missed dose. If vomiting occurs after taking avatinib, patients do not need to repeat the dose and should continue with the next scheduled dose.

In addition, patients should pay close attention to their physical condition during treatment with avatinib and report any abnormal reactions to their doctors in a timely manner. Doctors will make necessary adjustments to the dosage based on the patient's specific conditions to ensure the safety and effectiveness of the treatment.

In summary, avatinib, as an innovative tyrosine kinase inhibitor, plays an important role in the treatment of gastrointestinal stromal tumors and systemic mastocytosis. Patients should strictly follow the doctor's instructions and use avatinib rationally in order to obtain the best therapeutic effect.

Reference: https://www.drugs.com/pro/ayvakit.html